[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"semantic-dementia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:semantic-dementia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,70,108,134,159,185],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":39,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100609830","intervention-for-communication-quality-of-life-in-primary-progressive-aphasia-100609830",false,"NCT07219680","Intervention for Communication Quality of Life in Primary Progressive Aphasia","Intervention to Promote Communication Quality of Life for Persons With Language-Led Dementia and Their Partners: A Randomized Pilot Trial","Multi-PA","Inclusion Criteria for Persons with PPA:\n\n* A PPA (Gorno-Tempini et al., 2011) or \"PPA-plus\" (Mesulam et al., 2001) diagnosis\n* MMSE score of 15 or higher and must be able to produce single monosyllabic words intelligibly\n* Must speak English, Spanish or both languages (i.e., bilingual speakers of English or Spanish)\n* Hearing and vision adequate for participation in teleconference meetings\n* Must have a study partner available (someone who will commit to attending teleconference sessions, as needed, during assessment and treatment phases)\n\nInclusion criteria for Care Partners:\n\n* Partners must express willingness to attend and participate in assessment and treatment sessions, including those targeting dyadic communication goals\n* Partners must speak English, Spanish or both languages (i.e., bilingual speakers of English or Spanish)\n* Partner's hearing and vision should be adequate for participation in teleconference meetings\n\nThe participant and\u002For study partner must have basic experience using a computer.\n\nExclusion criteria for persons with PPA:\n\n* Other central nervous system or medical diagnosis that can account for symptoms\n* Psychiatric diagnosis that can account for symptoms","ALL","40 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn whether a personalized, multi-component, virtual speech language treatment program can improve communication and quality of life for adults with primary progressive aphasia (PPA) and their primary communication partners. The study will enroll participants who speak English and\u002For Spanish.\n\nThe main questions the study aims to answer are:\n\n* Is the telerehabilitation program feasible and acceptable for people with PPA and their study partners?\n* Do participants with PPA and study partners find treatment beneficial?\n* What patterns of treatment response are seen in participants?\n* Which outcome measures are most useful for evaluating changes in communication and quality of life?\n\nResearchers will compare participants who receive intervention immediately to participants assigned to a waitlist control group (who will receive treatment after a delay) to see whether participation in the treatment program is associated with improvements in communication and quality of life.\n\nParticipants will:\n\n* Take part in speech language therapy sessions delivered by video visit that combine restorative, compensatory, and partner-focused communication strategies. Treatment may take place after a waiting period.\n* Receive education and communication training together with their partner.\n* Complete speech, language, and cognitive assessments.\n* Complete questionnaires about communication abilities, daily functioning, and quality of life.",[27,28,29,30,31,32,33,34,35,36,37,38],"Primary Progressive Aphasia(PPA)","Semantic Dementia","Logopenic Progressive Aphasia (LPA)","Nonfluent Aphasia, Progressive","Progressive Aphasia","Semantic Variant Primary Progressive Aphasia (svPPA)","Semantic Aphasia","Logopenic Variant Primary Progressive Aphasia","Logopenic Variant of Primary Progressive Aphasia (LPA)","Logopenic Progressive Aphasia","Nonfluent Variant Primary Progressive Aphasia (nfvPPA)","Nonfluent Progressive Aphasia",[40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56],"speech-language pathology","neurodegenerative disease","logopenic","nonfluent","semantic","script training","teletherapy","remote","multimodal communication training","partner training","augmentative and alternative communication","AAC","Communication Book","bilingual","Spanish","Hispanic","Latino","RECRUITING","2026-04-15",{"date":60,"type":61},"2026-04-21","ACTUAL",{"date":63,"type":61},"2026-04-01",{"date":65,"type":21},"2027-08",{"name":67,"class":68},"Maya Henry","OTHER",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":17,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":97,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100299199","the-swedish-biofinder-2-study-100299199","NCT03174938","The Swedish BioFINDER 2 Study","BioFINDER2","COHORT A: Cognitively healthy younger individuals (40-65 years of age) INCLUSION CRITERIA\n\n* Age 40-65 years\n* Absence of cognitive symptoms as assessed by a physician with special interest in cognitive disorders.\n* MMSE score 27-30 at screening visit.\n* Do not fulfill the criteria for MCI or any dementia according to DSM-V.\n* Speaks and understands Swedish to the extent that an interpreter is not necessary for the patient to fully understand the study information and cognitive tests.\n\nEXCLUSION CRITERIA\n\n* Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.\n* Current significant alcohol or substance misuse.\n* Significant neurological or psychiatric illness.\n* Refusing lumbar puncture, MRI or PET.\n\nCOHORT B: Cognitively healthy elderly individuals (66-100 years of age) INCLUSION CRITERIA\n\n* Age 66-100 years\n* Absence of cognitive symptoms as assessed by a physician with special interest in cognitive disorders.\n* MMSE score 26-30 at screening visit.\n* Do not fulfill the criteria for MCI or any dementia according to DSM-V.\n* Speaks and understands Swedish to the extent that an interpreter is not necessary for the patient to fully understand the study information and cognitive tests.\n\nEXCLUSION CRITERIA\n\n* Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.\n* Current significant alcohol or substance misuse.\n* Significant neurological or psychiatric illness.\n* Refusing lumbar puncture, MRI or PET.\n\nCOHORT C: Subjective cognitive decline and mild cognitive impairment INCLUSION CRITERIA\n\n* Age 40-100 years.\n* Referred to the memory clinics due to cognitive symptoms experienced by the patient and\u002For informant. These symptoms do not have to be memory complaints, but could also be executive, visuospatial, language, praxis, psychomotor or social cognitive complaints.\n* MMSE score of 24 - 30 points.\n* Do not fulfill the criteria for any dementia (major neurocognitive disorder) according to DSM-V.\n* The medical doctor (after clinical assessments, cognitive testing, CSF analyses and structural brain imaging) believes the cognitive complaints are caused by an incipient neurocognitive disorder of any sort. This is defined as any case fulfilling the criteria above (i.e. both SCD and MCI) with an abnormal CSF Aβ42\u002F40 ratio, which is strongly associated with brain Aβ pathology and prodromal Alzheimer's disease. Further, cases with MCI (=minor neurocognitive impairment) due to either Parkinson's disease, Lewy body disease, vascular neurocognitive disorder or frontotemporal dementia (please see Appendix below for clinical criteria and references) can also be included.\n* Speaks and understands Swedish to the extent that an interpreter is not necessary for the patient to fully understand the study information and cognitive tests.\n\nEXCLUSION CRITERIA\n\n* Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.\n* Current significant alcohol or substance misuse.\n* Refusing lumbar puncture, MRI or PET.\n\nCOHORT D: Dementia due to Alzheimer's disease INCLUSION CRITERIA\n\n* Age 40-100 years.\n* Referred to the memory clinics due to cognitive symptoms experienced by the patient and\u002For informant. These symptoms do not have to be memory complaints, but could also be executive, visuospatial, language, praxis or psychomotor complaints.\n* MMSE score of 12-26 points.\n* Fulfill the criteria for dementia (major neurocognitive disorder) due to Alzheimer's disease (DSM-V).\n* Speaks and understands Swedish to the extent that an interpreter was not necessary for the patient to fully understand the study information and cognitive tests.\n\nEXCLUSION CRITERIA\n\n* Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.\n* Current significant alcohol or substance misuse.\n* Refusing lumbar puncture, MRI or PET.\n\nCOHORT E: Other dementias INCLUSION CRITERIA\n\n* Age 40-100 years.\n* Fulfill the criteria for dementia (major neurocognitive disorder) due to FTD, PDD, DLB or subcortical VaD alternatively the criteria for PD, PSP, MSA, CBS or ALS.\n* Speaks and understands Swedish to the extent that an interpreter was not necessary for the patient to fully understand the study information and cognitive tests.\n\nEXCLUSION CRITERIA\n\n* Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.\n* Current significant alcohol or substance misuse.\n* Refusing lumbar puncture, MRI or PET.",true,"20 Years","100 Years",{"count":81,"type":21},2950,[24],"The Swedish BioFINDER 2 study is a new study that will launch in 2017 and extends the previous cohorts of BioFINDER 1 study (www.biofinder.se). BioFINDER 1 is used e.g. to characterize the role of beta-amyloid pathology in early diagnosis of Alzheimer's disease (AD) using amyloid-PET (18F-Flutemetamol) and Aβ analysis in cerebrospinal fluid samples. The BioFINDER 1 study has resulted in more than 40 publications during the last three years, many in high impact journals, and some the of the results have already had important implications for the diagnostic work-up patients with AD in the clinical routine practice.\n\nThe original BioFINDER 1 cohort started to include participants in 2008. Since then there has been a rapid development of biochemical and neuroimaging technologies which enable novel ways to the study biological processes involved in Alzheimer's disease in living people. There has also been a growing interest in the earliest stages of AD and other neurodegenerative diseases. With the advent of new tau-PET tracers there is now an opportunity to elucidate the role of tau pathology in the pathogenesis of AD and other tauopathies. The Swedish BioFINDER 2 study has been designed to complement the BioFINDER 1 study and to e.g. address issues regarding the role of tau pathology in different dementias and in preclinical stages of different dementia diseases. Further, the clinical assessments and MRI methods have been further optimized compared to BioFINDER 1. Detailed assessments of motor aspects and dual task performance, which is part of a sub-study named Motor-ACT: \"Motor aspects and activities in relation to cognitive decline and brain pathologies, has been added to further optimize assessment of motor function.",[85,86,87,88,89,90,28,91,92,93,94,95,96],"Dementia","Alzheimer Disease","Parkinson Disease","Lewy Body Disease","Parkinson-Dementia Syndrome","Frontotemporal Degeneration","Progressive Nonfluent Aphasia","Progressive Supranuclear Palsy","Corticobasal Degeneration","Multiple System Atrophy","Mild Cognitive Impairment","ALS (Amyotrophic Lateral Sclerosis)",[98],"Early diagnosis, biomarker, PET, MRI, β-amyloid, tau, CSF, cognitive test",{"date":100,"type":61},"2026-04-06",{"date":102,"type":61},"2017-05-15",{"date":104,"type":21},"2036-12",{"name":106,"class":68},"Skane University Hospital",2,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":116,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":133},"100453440","phase-1-veri-t-a-trial-of-verdiperstat-in-patients-with-svppa-due-to-tdp-43-pathology-100453440","NCT05184569","Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology","Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of Oral Verdiperstat (BHV-3241) in Patients With Semantic Variant Primary Progressive Aphasia (svPPA) Due to TDP-43 Pathology","Veri-T-001","Inclusion Criteria:\n\n1. Between 18 and 85 years of age (inclusive) at the initial screening visit;\n2. Meets 2011 consensus criteria for svPPA (Gorno-Tempini et al. 2011);\n3. MRI at screening is consistent with the underlying svPPA with no large strokes or severe white matter disease (Fazekas Grade ≤2; Fazekas et al. 1987);\n4. CDR® plus NACC FTLD (Miyagawa et al. 2020) global score at screening ≤1;\n5. The following medications are allowed, but must be stable for 2 months prior to the initial screening visit:\n\n   1. Food and Drug Administration (FDA)-approved Alzheimer's disease (AD) medications;\n   2. FDA-approved psychotropic medications;\n6. Other medications (except those listed under exclusion criteria) are allowed as long as the dose is stable for 30 days prior to the initial screening visit;\n7. Has a reliable study partner who agrees to accompany the participant to visits, and spends at least 5 hours per week with the participant;\n8. Agrees to 2 LPs;\n9. Signed and dated written informed consent obtained from the participant and the participant's study partner in accordance with local Institutional Review Board (IRB) regulations;\n10. WOCBP must agree to abstain from sex or use highly effective birth control that includes two methods of contraception (one of which must be a barrier method) for the duration of the screening period, the RDBPC treatment period, and for 30 days after the last dose of study drug (active or placebo);\n11. Males must agree to abstain from sex with WOCBP or use an adequate method of contraception for the duration of the RDBPC treatment period and for 90 days after the last dose of study drug (active or placebo);\n12. Able to swallow pills whole without crushing or chewing.\n\nExclusion Criteria:\n\n1. A clinical diagnosis of probable AD (McKhann et al. 2011) or previous biomarker evidence of AD biology using amyloid positron emission tomography (PET) imaging, CSF amyloid beta (Aβ)\u002Ftotal tau (t-tau) ratio, CSF\u002Fplasma amyloid beta isoform with 40 amino acid residues (Aβ40)\u002Famyloid beta isoform with 42 amino acid residues (Aβ42) ratio, or plasma phosphorylated tau \\[phosphorylated tau at residue 181 (p-tau181) and phosphorylated tau at residue 217 (p-tau217)\\] assessments;\n2. A clinical diagnosis of a comorbid FTLD-associated clinical syndrome other than svPPA, including:\n\n   1. logopenic primary progressive aphasia (lvPPA; Gorno-Tempini et al. 2011);\n   2. non-fluent\u002Fagrammatic variant primary progressive aphasia (nfvPPA; Gorno-Tempini et al. 2011);\n\n      * c. behavioral variant for frontotemporal dementia (bvFTD; Rascovsky et al. 2011). Patients who meet diagnostic criteria for svPPA (Gorno-Tempini et al. 2011) may still be included if they have a secondary diagnosis of bvFTD, so long as the PI can reasonably attribute their disinhibition, dietary changes, compulsions, and\u002For loss of empathy to anterior temporal lobe atrophy (Seeley et al. 2005) and MRI is consistent with right anterior atrophy (or left temporal atrophy in participants with suspected right hemispheric language dominance);\n\n   d. progressive supranuclear palsy (PSP; Höglinger et al. 2017); e. corticobasal syndrome (CBS; Armstrong et al. 2013);\n3. Any other medical condition other than FTLD that is likely to account for cognitive or behavioral deficits (e.g., uncontrolled seizure disorder, stroke, vascular dementia, substance abuse or alcoholism, Lewy body disease);\n4. History of uncontrolled thyroid disease or evidence thereof \\[i.e., abnormal free thyroxine (T4) levels and thyroid stimulating hormone (TSH) \\> 10 milli-international units (mIU)\u002Fliter (L) at screening (confirmed by repeat)\\];\n5. Serious autoimmune disease, or ongoing immunocompromised state;\n6. History of significant cardiovascular, hematologic, renal, or hepatic disease (or laboratory evidence thereof at screening);\n7. History or presence of gastrointestinal (GI) or other disease known to interfere with absorption, distribution, metabolism, or excretion of drugs, or a history of surgery known to interfere with absorption or excretion of drugs (i.e., gastric bypass);\n8. Within 1 year prior to initial screening visit or between screening and baseline (pre-dose Day 1), any of the following: myocardial infarction; hospitalization for congestive heart failure; hospitalization for, or symptoms of, unstable angina; or syncope;\n9. History of major psychiatric illness or untreated depression that in the opinion of the PI would pose a safety risk or interfere with the appropriate interpretation of study data;\n10. Neutrophil count \\\u003C1,500\u002Fcubic millimeter (mm3), platelets \\\u003C100,000\u002Fmm3, serum creatinine \\>1.5 x upper limit of normal (ULN), total bilirubin (TBL) \\>1.5 x ULN, alanine aminotransferase (ALT) \\>1.5 x ULN, aspartate aminotransferase (AST) \\>1.5 x ULN, or international normalized ratio (INR) \\>1.2 at screening (confirmed by repeat);\n11. Evidence of any clinically significant findings on screening or baseline evaluations which, in the opinion of the PI would pose a safety risk or interfere with appropriate interpretation of study data;\n12. Corrected QT interval by Fridericia (QTcF) ≥ 470 milliseconds (msec) or uncontrolled arrhythmia or frequent premature ventricular contractions (PVCs; \\>5\u002Fminute) or Mobitz Type II second or third degree atrioventricular (AV) block or left bundle branch block or right bundle branch block with a QRS duration ≥ 150 msec or intraventricular conduction defect with a QRS duration ≥ 150 msec or evidence of acute or sub-acute myocardial infarction or ischemia or other ECG findings at screening or baseline that, in the PI's opinion, would preclude participation in the study;\n13. Pathologic renal findings at screening as defined by the presence of either of the following criteria:\n\n    1. Estimated glomerular filtration rate (eGFR) \\[determined by the Modification of Diet in Renal Disease (MDRD) Study equation\\] \\\u003C 30 milliliter (mL)\u002Fminute\u002F1.73 square meter (m2). The MDRD Study equation is as follows: eGFR (mL\u002Fminute\u002F1.73 m2) = 175 x (Scr)-1.154 x (Age)-0.203 x (0.742 if female) x (1.212 if African American), where Scr = serum creatinine in mg\u002Fdeciliter (dL) as measured by a method calibrated to an isotope dilution mass spectrometry (IDMS) reference method;\n    2. Serum creatinine ≥ 2.5 mg\u002FdL;\n14. Hemoglobin A1C \\>7.5% at screening (confirmed by repeat);\n15. Current or recent history (within four weeks prior to initial screening visit) of a clinically significant bacterial, fungal, or mycobacterial infection;\n16. Current clinically significant viral infection, including \"known\" positive status for human immunodeficiency virus (HIV) (i.e., based on prior testing; HIV testing will not be performed as part of the screening evaluations for this trial);\n17. Major surgery within four weeks prior to initial screening visit;\n18. Blood transfusion within 4 weeks of initial screening visit;\n19. History of stem cell treatment;\n20. Any contraindication for MRI or unable to tolerate MRI at screening;\n21. Any contraindication to or unable to tolerate LP at screening, including the use of anti-coagulant medications such as warfarin. Daily administration of 81 mg aspirin will be allowed as long as the dose is stable for 30 days prior to the initial screening visit;\n22. Participants who, in the opinion of the PI, are unable or unlikely to comply with the dosing schedule or study evaluations;\n23. Prior treatment with verdiperstat;\n24. Treatment with another investigational drug within 30 days or 5 half-lives of drug before initial screening visit, whichever is longer. Treatment with investigational drugs other than verdiperstat while on study will not be allowed;\n25. Treatment with systemic corticosteroids or steroid sparing systemic immunosuppressive agents within 30 days or 5 half-lives of drug before initial screening visit, whichever is longer. Treatment with systemic corticosteroids or other systemic immunosuppressive therapy while on study will not be allowed;\n26. Treatment with strong inhibitors of CYP1A2 (i.e., ciprofloxacin, enoxacin, fluvoxamine) within 30 days or 5 half-lives of drug before initial screening visit, whichever is longer. Treatment with strong inhibitors of CYP1A2 while on study will not be allowed;\n27. Known hypersensitivity to the inactive ingredients in the study drug products (active or placebo);\n28. Known to be pregnant or lactating, or positive pregnancy test at screening or baseline (pre-dose Day 1);\n29. Cancer within 5 years of initial screening visit, except for basal cell carcinoma;\n30. History or evidence at screening of known disease-associated mutations associated with FTLD without trans-activation response deoxyribonucleic acid-binding protein of 43 kilodaltons (TDP-43) inclusions \\[e.g., mutations in the genes encoding chromatin-modifying protein\u002Fcharged multivesicular body protein B2 (CHMPB2), microtubule-associated protein tau (MAPT), or fused in sarcoma (FUS)\\].","18 Years","85 Years",{"count":119,"type":21},64,[121],"PHASE1","The purpose of the study is to test the safety and tolerability of twice daily Verdiperstat in patients with semantic variant primary progressive aphasia (svPPA) due to frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP). Three-fourths of the participants will receive Verdiperstat and one-fourth will receive Placebo during the 24-week treatment duration.",[28],"2025-10-13",{"date":126,"type":61},"2025-10-15",{"date":128,"type":61},"2022-04-14",{"date":130,"type":21},"2026-09-30",{"name":132,"class":68},"Peter Ljubenkov, MD",5,{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":77,"sex":17,"minAge":116,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":144,"phases":4,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":69},"100283059","diagnosing-frontotemporal-lobar-degeneration-100283059","NCT02964637","Diagnosing Frontotemporal Lobar Degeneration","Multimodal Assessment for Predicting Specific Pathological Substrate in Frontotemporal Lobar Degeneration","Inclusion Criteria:\n\n* Participant must have a reliable study partner who can provide an independent evaluation of functioning.\n* Able to read, understand and speak English for neuropsychological testing.\n* All subjects must meet one of these diagnostic criteria (A) probable behavioral variant FTD, (B) MRI-supported non-fluent variant PPA; (C) MRI-supported semantic variant PPA and \\[18F\\]T807 negative (D) probable CBS: using current criteria for CBS(27); (E) PSP: inclusion criteria for PSP are based upon the National Institute of Neurological Disorders and Stroke Society of Progressive Supranuclear Palsy (NINDS-SPSP) (F) FTD-MND\n* Control subjects must have a normal neurological exam, a CDR sum of boxes = 0, and MMSE score equal to or greater than 28\n\nExclusion Criteria:\n\n* Patients with clinical, imaging or CSF A beta\u002F tau profile consistent with AD\n* History of traumatic brain injury, brain tumors, stroke or other neurological or psychiatric disorders that can explain symptoms will be excluded.\n* Premenopausal women will be asked to consent to a pregnancy test prior to each scan as pregnant women will be excluded from study because of potential harm to fetus from PET study.\n* Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body.","90 Years",{"count":143,"type":21},100,"OBSERVATIONAL","To establish diagnostic tools to make an accurate clinical and pathological diagnosis of patients with clinical FTLD syndromes",[147,92,148,28,91,149],"Corticobasal Syndrome","Behavioral Variant Frontotemporal Dementia","Amyotrophic Lateral Sclerosis And\u002For Frontotemporal Dementia","2025-03-25",{"date":152,"type":61},"2025-03-30",{"date":154,"type":4},"2015-08",{"date":156,"type":21},"2026-12",{"name":158,"class":68},"University Health Network, Toronto",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":77,"sex":17,"minAge":116,"maxAge":117,"enrollmentInfo":167,"targetDuration":4,"studyType":144,"phases":4,"briefSummary":169,"conditions":170,"keywords":171,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":69},"100500728","memory-and-social-interactions-100500728","NCT05800028","Memory and Social Interactions","Memory and Social Interactions: Study in Alzheimer's Disease and Semantic Progressive Aphasia","MEM&SO","Inclusion criteria:\n\n* AD group: Age between 50 and 85 years, Diagnosis of probable Alzheimer's disease dementia with amnestic presentation and documented decline following the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.\n* SPPA group: Age between 50 and 85 years, Diagnosis of the semantic variant of primary progressive aphasia following the classification of primary progressive aphasia and its variants.\n* HC group: Age between 50 and 85 years, Matched in age and sociocultural status with one of the AD or SPPA patients, No cognitive complain, No recent reduction in social or cognitive activities, No contraindication to MRI examination.\n* Partners: Age over 18 years of age , No cognitive complaints, Social interactions of at least two hours per week for at least 5 years with one of the individuals of the other three groups.\n\nExclusion criteria (for all groups):\n\n* Deprivation of liberty by judicial or administrative decision\n* Not being a member of a social security system\n* Concurrent participation in a therapeutic drug trial\n* Uncorrected visual and\u002For auditory disorders that are sufficiently significant to interfere with the protocol\n* History of neurological disorders (stroke, epilepsy, head trauma with loss of consciousness for more than one hour)\n* History of chronic alcoholism or drug abuse\n* History within the last 10 years of a clinically significant major psychiatric disorder\n* Cancer within the past 5 years, except for squamous cell carcinoma\n* Use of medications that may affect cognitive and\u002For brain function. Given the number of molecules involved and the dosages, the principal investigator will judge on a case-by-case basis whether regular use of certain medications will interfere with the study",{"count":168,"type":21},192,"Memory and social interaction are intimately linked. On the one hand, social interaction is a privileged context for learning, and on the other hand, appropriate social interactions involve remembering the partners encountered and previous exchanges. People with Alzheimer's disease classic syndrome variant (AD) have a major impairment of episodic memory, while people with the semantic variant of primary progressive aphasia (SPPA) are characterized by semantic disorders in the foreground, associated with changes in their social behavior with a tendency to egocentricity. In both cases, patients frequently have reduced social interactions. Although social interaction situations seem to constitute a privileged learning context, their effectiveness for patients with cognitive disorders must be evaluated and the conditions under which they are effective must be established. The main objective of this study is to determine whether social interaction constitutes a beneficial context for learning new information and whether the presence of social behavior disorders alters this benefit. More broadly, the goal is to better understand the mechanisms underlying the possible beneficial effect of learning in social contexts and to clarify the links between memory performance in different social contexts, cognitive disorders, social behavioral changes and personality traits. Finally, a description will be made of the brain substrates associated with memory performance obtained during learning in social contexts in order to investigate their particularities. Thirty couples each including a person with AD, 16 couples each including a person with SPPA and 46 couples of persons without cognitive complaints (HC), one of which will be matched in gender and age to one of the patients, will be included in the study. Participants will perform image location learning in a grid, in three social contexts in which both members of the couple are involved: 1) simple presence of others, 2) by observation and 3) in collaboration. A psychometric assessment including social cognition and classical tests assessing memory, and questionnaires concerning global executive functioning, social behavior and personality will be offered to all participants. Patients in the AD and SPPA groups and the matched individual in the HC group will undergo anatomical and functional brain magnetic resonance imaging (MRI).",[86,28],[172,173,174,86,175],"Memory","Social Interaction","Personality","Aphasia, Primary Progressive","2024-09-19",{"date":178,"type":61},"2024-09-20",{"date":180,"type":61},"2023-03-10",{"date":182,"type":21},"2026-12-31",{"name":184,"class":68},"University Hospital, Caen",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":17,"minAge":116,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":144,"phases":4,"briefSummary":194,"conditions":195,"keywords":196,"overallStatus":197,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":69},"100532893","revealing-engagement-dynamics-among-semantic-dementia-patients-100532893","NCT06218732","Revealing Engagement Dynamics Among Semantic Dementia Patients","Understanding Participation Habits: An Observational Investigation Within Semantic Dementia Clinical Trials","Inclusion Criteria:\n\n* Patients diagnosed with semantic dementia\n* Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed\n* Subjects willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examination.\n\nExclusion Criteria:\n\n* Refusal of consent\n* Women of childbearing potential without a negative pregnancy test; or women who are lactating.\n* Any serious and\u002For unstable pre-existing medical disorders",{"count":193,"type":21},500,"The study intends to investigate the personal experiences of semantic dementia patients who take part in a separate clinical study including a specific medication intervention. The major focus will be on closely following individuals' rates of trial completion and withdrawal.\n\nThe data collected from this study will help improve future outcomes for all semantic dementia as well as those in under-represented demographic groups.",[28],[28],"NOT_YET_RECRUITING","2024-01-12",{"date":200,"type":61},"2024-01-23",{"date":202,"type":21},"2025-02",{"date":204,"type":21},"2027-02",{"name":206,"class":207},"Power Life Sciences Inc.","INDUSTRY"]